Complement C3 Antibody (2898) Summary
| Immunogen |
Peptide CARASHLGLA (last nine amino acids of C3a-desArg).
|
| Specificity |
The last nine amino acids (C3a-desArg) of Complement protein C3
|
| Isotype |
IgG1
|
| Clonality |
Monoclonal
|
| Host |
Mouse
|
| Gene |
C3
|
| Purity |
Protein A or G purified
|
| Innovators Reward |
Test in a species/application not listed above to receive a full credit towards a future purchase.
Learn about the Innovators Reward
|
Applications/Dilutions
| Dilutions |
|
|
| Application Notes |
This product can be used for Immunoassay and Western blotting. Western Blot: A reduced sample treatment and SDS-PAGE was used. The band size is ~95 and 8.2 kDa for C3 and C3a respectively (Ref.1).
|
|
| Publications |
|
Reactivity Notes
Human.
Packaging, Storage & Formulations
| Storage |
Store at 4C. Do not freeze.
|
| Buffer |
0.2 um filtered solution in PBS and 0.1% BSA
|
| Preservative |
0.02% Sodium Azide
|
| Concentration |
0.1 mg/ml
|
| Purity |
Protein A or G purified
|
Alternate Names for Complement C3 Antibody (2898)
- AHUS5
- ARMD9
- ASP
- C3 and PZP-like alpha-2-macroglobulin domain-containing protein 1
- complement C3
- complement component 3
- complement component C3
- CPAMD1acylation-stimulating protein cleavage product
Background
The monoclonal antibody 2898 recognizes the C-terminus of human complement protein C3a. The antibody recognizes intact C3, C3a as well as C3a-desArg. C3 is the most abundant protein of the complement system with serum protein levels of about 1.3 mg/ml. The complement system is an important part of the humoral response in innate immunity, consisting of three different pathways. The third complement component, C3, is central to the classical, alternative and lectin pathways of complement activation. Activation products of the complement cascade contain neo-epitopes that are not present in the individual native components. Monoclonal antibodies detecting neo-epitopes have been used for direct quantification of activation at different steps in the complement cascade. The synthesis of C3 is tissue-specific and is modulated in response to a variety of stimulatory agents. An inherited deficiency of C3 predisposes the person to frequent assaults of bacterial infections. In ulcerative colitis, and idiopathic chronic inflammatory bowel disease, the deposition of C3 in the diseased mucosa has been reported. Proteolysis by certain enzymes results in the cleavage of C3 releasing C3a anaphylatoxin and C3b. C3a is a protein of 74 amino acids. C3a itself is very short-lived and in serum is cleaved rapidly into the more stable C3a-desArg (also called acylation stimulating protein, ASP). Therefore, measurement of C3a-desArg allows reliable conclusions about the level of complement activation in the test samples. C3a is a mediator of local inflammatory processes. It induces smooth muscle contraction, increases vascular permeability, and causes histamine release from mast cells and basophilic leukocytes. C3a is involved in inflammatory reactions seen in gram-negative bacterial sepsis, trauma, ischemic heart disease, post-dialysis syndrome and a variety of autoimmune diseases.
